Amphotericin B and N-D-ornithyl amphotericin B methyl ester were compared for therapeutic efficacies against experimentally induced cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis in rabbits. Antifungal activity of the two polyenes in vitro was similar for the yeasts used in these experiments.
The nephrotoxicity of amphotericin B can be mitigated by esterification of the parent molecule (13, 15) . When a methyl group is esterified onto the carboxyl group of amphotericin B, antifungal activity is retained, but nephrotoxicity is reduced (15) . Amphotericin B methyl ester has proved effective against candida, cryptococci, blastomyces, and coccidioides in animals (4, 7, 17) and has been used in humans (6, 11) , but the drug was abandoned because it seemed to be neurotoxic (6) .
Another polyene congener with less cardiac and renal toxicity than amphotericin B is N-D-ornithyl amphotericin B methyl ester (SCH 28191), which is soluble in water (15) . This compound was selected by others from many polyenes for further evaluation because it retained antifungal activity similar to amphotericin B in vitro and its lower toxicity was appealing (15, 21) . In this study we compared the therapeutic activities of N-D-amphotericin B methyl ester, studied the pharmacokinetics and in vivo activity of this polyene ester, and compared its activity with that of its parent amphotericin B against experimentally induced cryptococcal meningitis (23) and Candida albicans endocarditis (25) and pyelonephritis in rabbits. We attempted to correlate the results with the in vitro activities and the concentrations attained in the circulating blood and cerebrospinal fluid (CSF) of these animals.
MATERIALS AND METHODS
Animals. New Zealand White rabbits (2 to 3 kg) were housed in separate cages and given Rabbit Chow (Ralston Purina Co., St. Louis, Mo.) and water ad libitum. kindly donated amphotericin B powder for in vitro studies; this was dissolved in dimethyl sulfoxide. For animal treatment studies the commercial preparation of amphotericin B, which contains Desoxycholate (E. R. Squibb & Sons Inc., Princeton, N.J.), was used. N-D-ornithyl amphotericin B methyl ester also was provided by Schering; it was dissolved in sterile water for both in vitro and in vivo studies.
In vitro susceptibility testing. (i) To measure the MIC, an overnight growth of the yeast on a Sabouraud slant was taken up with a swab, suspended in saline, and adjusted by optical density to a final concentration of 103 to 104 CFU/ml in 1-ml tubes of Sabouraud broth. After the addition of antifungal agents, these tubes were incubated at 30°C for 24 h. The endpoint for growth inhibition was read as the first tube in the series which showed no visible growth. Subcultures of 0.1 ml onto Sabouraud agar were made for colony counts to quantitate the survivors; 99.9% kill of the original inoculum was defined as the minimal fungicidal concentration (26) .
(ii) Blood for serum fungistatic and fungicidal titers was drawn after the first dose given to animals with endocarditis. Titers were measured with the test strain of C. albicans at an inoculum of 105 CFU/ml. Dilutions of serum from treated rabbits were made in Sabouraud broth. Endpoints were read after 24 h, as above.
(iii) In vitro antifungal activity of the two polyenes in the presence of rabbit CSF was determined after adding 104 CFU of Cryptococcus neoformans (DP strain) to normal rabbit CSF and then adding various concentrations of polyenes. Samples were removed at 2, 24, 48, and 72 h for subculture on Sabouraud agar to quantitate the number of viable yeasts.
Antimicrobial assays. Bioassay was performed on sera obtained from 2 to 6 randomly chosen rabbits infected with C. neoformans on day 1 cerevisiae as the test organism. Previous studies with this assay, which has a lower limit of sensitivity of approximately 0.3 ,ug/ml, failed to detect amphotericin B in the CSF of treated animals (22) . A more sensitive high-pressure liquid chromatographic (HPLC) assay (14) was-also performed on CSF and serum samples from infected animals on days 1 and 6 of treatment by Dr. Lin of Schering Corp. The assay for CSF samples had a lower limit of sensitivity for amphotericin B of 0.002 ,ug/ml; the sensitivity for N-D-ornithyl amphotericin B methyl ester was 0.008 ,ug/ml. For serum the lower limit of sensitivity for both polyenes was 0.015 ,ug/ml.
Organisms. A human'CSF isolate of C. neoformans (DP strain) used in prev'ious experiments with cortisone-treated rabbits (23) was again used in the meningitis experiments. A clinical isolate of C. albicans (Carter strain) was used for the endocarditis and pyelonephritis experiments. These yeasts were maintained by serial transfer on Sabouraud slants.
Production of cryptococcal meningitis. Cultures' (4 'days old) of C. neoformans o'n Columbia blood agar plates containing 100 K.g of chloramphenicol per ml were taken up on cotton swabs, suspended in 0.015 M phosphate-buffered saline, and adjusted to approximately 5 x 107 CFU/ml. Rabbits, treated i.m. with 2.5 mg of cortisone acetate (Merck Sharp & Dohme, West Point, Pa.) per kg of body weight 24 h before inoculation of yeast, were sedated, and 0.3 cc of the yeast suspension was inoculated intracisternally. Rabbits were then treated daily with i.m. injections of 2.5 mg of cortisone acetate per kg for 18 days. At 4 days after inoculation, CSF was aspirated, and serial dilutions of CSF in'phosphate-buffered saline were plated on Columbia blood agar plates containing chloramphenicol to prove that infection had been established. Rabbits were then randomly divided into treatment groups. Treatment was started on day 4 of infection, and CSF was withdrawn for yeast co'unts on days 7, 11, 14, and 18 of infection (that is, after days 3, 7, 10, and 14 of treatment). The duration of treatment was 2 weeks.
Production of C. albicans endocarditis. Rabbits were anesthetized, and the right carotid artery was' exposed. A polyethylene catheter (PE-50; Clay-Adams, Parsippany, N.J.) was inserted across the aortic valve. The catheter was left in place until the rabbit was killed. At 24 h after catheter insertion, 1 ml of 1 x 107 CFU/ml of C. albicans was inoculated into the marginal ear vein. Rabbits were randomly divided into treatment groups 24 h later, receiving daily treatment for 7 days. After the last treatment (24 h), rabbits were killed, and the heart and kidneys were removed. Statistical analysis. In evaluating the effect of treatment on yeast counts, the slopes of curves for each rabbit with meningitis were'compared with a t test for unpaired means. Fisher's exact test was used to compare the numbers with sterile CSF or tissue in each group. RESULTS The in vitro activity in Sabouraud broth of amphotericin B and N-D-ornithyl amphotericin B methyl ester against the two yeast strains used was similar. The mean MICs of the two yeast species for amphotericin B and N-D-ornithyl amphotericin B methyl ester follow:' for amphotericin B, C. neoformans (0.03 p.g/ml) and C. albicans (0.04 ,ug/ml); for N-D-ornithyl amphotericin B methyl ester, C. neoformans (0.07',ug/ml) and C. albicans (0.08 ,ug/ml). The minimum fungicidal concentrations varied on repeated testing between 0.25 to 5.0 ,g/ml for both yeasts but were consistently similar within each run.' Moreover, the activity of the two polyenes against 'C. neoformans was indistinguishable when these 'drugs were added directly to CSF in vitro. The cryptococcal viability was not affected when incubation occurred in a subinhibitory dose (0.01 ,ug/ml) of the two drugs in normal CSF. The rate of kill in vitro for both amphotericin B and N-D-ornithyl amphotericin B methyl ester in CSF was identical at concentrations of 0.1 and 1.0 ,g/ml (results not shown).
Antifungal drug levels in serum of 2 to 6 randomly chosen rabbits infected with C. neoformans were measured by bioassay (Table 1) . These levels were measured after a single i.v. dose. The concentration of N-Q-omithyl amphotericin B methyl ester in serum was higher than that of amphotericin B at the same dose, but both drugs were measurable over the 24-h Drug concentrations measured by HPLC are also shown in Table 1 . The'sera and CSF measurements were done in rabbits infected with C. neoformans after the first dose. These samples were from different rabbits than those used to measure the drug by bioassay. Amphotericin B was detected in all CSF specimens but levels were very low, between 0.002 and 0.010 ,ug/ml. This is well below the amount that has any observable antifungal activity in vitro. After repeated dosing, accumulation did not occur; CSF levels remained constant after daily doses for 6 days (range, 0.006 to 0.008 ,u.g/ml). N-D-ornithyl amphotericin B methyl ester was detected in the. CSF of only two rabbits, at 0.029 and 0.027' ,..g/ml. However, the lower limit of susceptibility of this assay (0.008 ,ug/ml) was significantly higher than that for amphotericin B; it was als'o higher than most measured concentrations of amphotericin B in CSF ( than 90% of the kidneys and their collecting systems were sterilized. Thus, as was observed in C. albicans endocarditis, the two drugs appeared to be similar in efficacy at the same doses. Unlike the results with endocarditis, for kidney infections there was evidence of increasing efficacy with increasing dosage. DISCUSSION Amphotericin B remains the standard against which all newer antifungal agents must be measured. N-D-ornithyl amnphotericin B methyl ester is a water-soluble compound which was selected after a careful study of various amphotericin B congeners for in vitro activity against yeasts (12, 21) ; it also reduced acute toxicity on the cardiovascular system and long-term effects on the kidney (4). Previous studies with experimental animal infections of candidiasis (8) , aspergillosis (9) , histoplasmosis (16) , and blastomycosis (19) showed that N-D-ornithyl amphotericin B methyl ester was active against these fungi in vivo.
We found little difference between the N-D-ornithyl amphotericin B methyl ester and its parent compound with respect to in vitro susceptibility of the two species of yeast used in these experiments. We were able to give significantly higher doses of the methyl ester congener compared with amphotericin B, because the former has less acute toxicity.
Although no toxicity was evident in these short-term experiments, the possibility of neurotoxicity cannot be excluded.
The predictive value of fungal susceptibility testing has not been established. Stiller et al. (27) have suggested that in vitro susceptibility to flucytosine could be used to predict outcome of treatment in vivo in murine candidiasis, and Ryley et al. (24) have shown in vitro and in vivo correlation with 'several'ketoconazole-resistant strains in murine infections. However, in a trial of ketoconazole in humans no relationship was found between in vitro testing of isolates and clinical response (5) . For amphotericin B, it has been extremely difficult to correlate in vitro activity with in vivo response. Stimulation of cellular host defenses by amphotericin B, separate from its direct antifungal capacity, may play an important role in successful treatment (10) . Our study empha'sizes the importance of in vivo examination of these agents. Neither in vitro susceptibilities nor pharmacokinetics can explain why amphotericin B was distinctly more' effective than N-D-ornithyl amphotericin B methyl ester in the treatment of cryptococcal meningitis in rabbits. Similar superiority of the parent compound over congeners in the treatment of experimental mycoses has been found by other'investigators with another methyl ester compound (4, 5, 17 
